All In Biotech

Drug Trial Radar · NCT07187375

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

7

Actual

Start

Sep 30, 2025

Primary completion

Sep 6, 2029

Study completion Oct 4, 2029

Sponsor

Lead sponsor
Neurocrine Switzerland GmbHNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 23 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).

Conditions

  • Congenital Adrenal Hyperplasia

Interventions

  • CrinecerfontDrug

    Oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Concentration of CrinecerfontTime frame: Days 7 and 15

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Berlin, Germany

  • Neurocrine Clinical Site

    Düsseldorf, Germany

  • Neurocrine Clinical Site

    Heidelberg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.